Exiqon secures Euro17m in round C
Copenhagen - The Danish real-time PCR specialist Exiqon A/S has completed a third round of financing at the beginning of June providing some Euro17 million in additional funding. The funding is earmarked for developing products from the company's growing product portfolio, for increasing sales and marketing capabilities and for repaying loans. This brings the total funding since incorporation in 1996 to Euro31 million. The current investors include Teknoinvest as lead investor and Scandinavian Life Science Venture, Nobel Group, LD Pensions, BioFund, and Danske Bank, all of which participated in the previous round of financing.
The company has recently completed a major distribution agreement with Roche Diagnostics for Exiqon's ProbeLibrary™ real-time PCR kits, addressing one of the largest market segments within life science. Exiqon is now strengthening its product portfolio as well as sales and marketing efforts and is launching a number of new miRCURY™ products for microRNA analysis as well as products in other high-growth areas. “Getting high-value products on the market is essential to our business and it has been the main focus for Exiqon during the past couple of years” says Exiqon's President and CEO Lars Kongsbak.